Last reviewed · How we verify

NCT05810727

Atrial Fibrillation Data Linkage Non-Interventional Study

Completed Last updated 20 November 2025
What this trial tests

trial in Atrial Fibrillation in 12,556 participants. Completed in 23 October 2025.

Timeline
21 August 2025
Primary endpoint
23 October 2025
23 October 2025

Quick facts

Lead sponsorPfizer
StatusCompleted
Study typeOBSERVATIONAL
Enrollment12,556
Start date21 August 2025
Primary completion23 October 2025
Estimated completion23 October 2025
Sites1 location across South Korea

Conditions studied

Sponsor

Pfizer — full company profile →

Who can join

18 and older, any sex, with Atrial Fibrillation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to understand temporal changes in clinical features and functions, and the relationship with outcomes of atrial fibrillation (AF). AF is a problem with speed or pattern that the heart beats. It is the most common type of arrythmia. The study will use data linkage of a single center patient data and national claims database in Korea. This study does not include an actual patient enrollment process.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Atrial Fibrillation

Currently open trials in the same condition.

Other Pfizer trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05810727.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing